Table 3.

Criteria of in vitro generated cells that they should meet to be used in cell therapy for liver diseases

Criteria	hPSC [98]	hESCs, iPSCs [103, 195]	hESC-derived HLCs [106]	ADHLPCs [112, 113]	Autologous iPSCs [87]	hESC-derived HLCs [196]
GMP-grade	√	×	×	√	×	×
Xeno-free	√	×	×	×	×	×
Immunogenicitya	NT	NT	NT	√b	√	NT
Tumorogenicity	NT	NT	√	√c	×	NT
Scalability	√	√	√	√	√	√
Resistance to cryopreservation	NT	NT	NT	√	NT	√
Long-term efficacy	NT	NT	√	√	√	√
Display mature hepatocyte functions	√	√	√	√	NT	√

NT not tested, ND not determined, GMP good manufacturing practice, ADHLPCs adult-derived human liver progenitor cells

^aFor in vivo use, immunocompromised (mouse) models were used

^bTested in Ref. [112]

^cTested in Ref. [113]